Joaquín Díaz Mediavilla

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

Bruno Paiva, Joaquín Martínez‐López, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2011 · 233 citations · Full text

Medicine, Hematology, Oncology +13

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Stéphane de Botton, Miguel Á. Sanz, Sylvie Chevret et al. · Leukemia · 2005 · 160 citations

Medicine, Hematology, Oncology +16

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.

MV Mateos, Joan Bladé, Joaquín Díaz Mediavilla et al. · Blood · 2004 · 39 citations

Medicine, Hematology, Pharmacotherapy +15

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients

Sandra Quijano, Antonio López, Ana Rasillo et al. · Blood · 2008 · 25 citations · Full text

Veterinary Medicine, Hematology, Pathology +17